公司已于近日获得了根据当地法律的规定需要在本次交易完成之前获得的 所有必要的境外反垄断审查机构的批准。 本次交易尚未正式交割，目前相关工作正在推进中。公司将密切关注本次交 易的进展，并按照相关法律法规的规定，及时履行信息披露义务，敬请广大投资 者理性投资，注意投资风险。 证券代码：002252 证券简称：上海莱士 公告编号：2025-045 上海莱士血液制品股份有限公司 关于通过境外反垄断审查 暨收购南岳生物制药有限公司股权的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 2025 年 3 月 26 日，上海莱士血液制品股份有限公司（以下简称"公司"） 与刘令安、长沙德信生物技术合伙企业（有限合伙）、陈玉、肖汉族、王香英及 南岳生物制药有限公司（以下简称"南岳生物"）签署《关于南岳生物制药有限 公司之股权转让协议》，收购该等转让方合计持有的南岳生物 87.9766%股权； 与湖南兴湘南岳私募基金合伙企业（有限合伙）、湖南兴湘隆银高新产业投资合 伙企业（有限合伙）（以下合称"湖南兴湘基金"）及南岳生物签署《关于南岳 生物制药有限公司 12.0234%股 ...

Core Viewpoint - The control of blood product company Palin Bio (000403.SZ) has been transferred to China National Pharmaceutical Group (Sinopharm), which may lead to the integration of Palin Bio and Tian Tan Bio (600161.SH), potentially reshaping the competitive landscape in the blood product industry [1][5][9]. Group 1: Company Control and Financials - On June 10, Palin Bio announced that its controlling shareholder, Qiongcheng Shengbang Yinghao Investment Partnership, plans to transfer its entire 21.03% stake to China National Biotechnology Co., Ltd. [1] - The transaction is valued at 38.44 billion yuan, with a share price of 24.96 yuan, representing a 47% premium over the closing price of 16.96 yuan on June 6 [3]. - The estimated price-to-earnings ratio for this transaction is close to 32 times, based on a projected net profit of 7.45 billion yuan for 2024 [3][4]. Group 2: Industry Competition and Market Position - The integration of Tian Tan Bio and Palin Bio could lead to a combined revenue of approximately 86.87 billion yuan, surpassing Shanghai Lai Shi's (002252.SZ) projected revenue of 81.76 billion yuan for 2024 [7][15]. - If the integration occurs, the combined entity would control at least 123 plasma collection stations and have a total plasma collection volume of 4,181 tons, significantly increasing market share to nearly 30% [7][16]. - The blood product industry is experiencing consolidation due to limited new entrants since 2001, with companies increasingly acquiring others to expand market share [16][17]. Group 3: Challenges and Future Outlook - The integration process may face challenges, particularly regarding the internal conflicts within Palin Bio, especially with its second-largest shareholder, Harbin Tongzhi Cheng Technology Development Co., Ltd. [10][11][14]. - The future of the blood product industry may depend on how effectively China National Pharmaceutical Group can manage these internal dynamics while pursuing further consolidation [9][14]. - The industry is also exploring innovative solutions to reduce reliance on human plasma, with several companies making progress in developing recombinant products [21][22].

Group 1 - The core issue leading to the termination of major asset restructurings among listed companies is the inability to reach an agreement on key terms, particularly the transaction price [5][6][7] - Since 2025, over 20 listed companies have announced the failure of significant asset restructurings, including well-known firms such as Guozhong Water, China Merchants Energy, and Haier Biomedical [1][5] - Companies like Yuehongyuan A and *ST Shuangcheng have also faced similar issues, primarily due to disagreements on pricing [7][11] Group 2 - Market environment changes and prolonged negotiation periods have contributed to the abandonment of restructuring plans, as seen in cases like Xinno and Antong Holdings [9][10] - The complexity of transaction structures and the presence of asset ownership issues have also been significant factors in the failure of mergers and acquisitions [11][12] - The need for effective communication and coordination among parties involved in the transaction is crucial to avoid misunderstandings and ensure successful negotiations [17][19] Group 3 - Recent policy initiatives, such as the revised "Major Asset Restructuring Management Measures," aim to enhance the merger and acquisition market's activity and success rates [14][15] - Companies are encouraged to conduct thorough due diligence and risk assessments as foundational steps in the merger process [16] - Establishing a joint working group and regular communication mechanisms can help address disputes and facilitate smoother negotiations [18][19]

Core Viewpoint - The acquisition of a controlling stake in Pailin Biological by China National Pharmaceutical Group signifies a significant shift in ownership and control within the blood products industry in China, with implications for market competition and consolidation strategies [2][3]. Group 1: Acquisition Details - Pailin Biological's controlling shareholder, Shengbang Yinghao Investment Partnership, plans to transfer its entire 21.03% stake to China National Pharmaceutical for a total cash consideration of 3.844 billion yuan [1][3]. - The transaction values Pailin Biological at 24.96 yuan per share, representing a 47% premium over its closing price of 16.96 yuan on June 6 [3]. - The estimated price-to-earnings (P/E) ratio for this transaction is approximately 32 times, based on Pailin's projected net profit of 745 million yuan for 2024 [3]. Group 2: Industry Context - The valuation of Pailin Biological is notably higher than that of several other A-share blood product companies, which have P/E ratios around 25 times, with only Boya Bio reaching 36 times [4]. - The scarcity of blood products in China, due to regulatory restrictions on new production facilities since 2001, underpins the rationale for China National Pharmaceutical's substantial investment [5]. Group 3: Competitive Landscape - Following the acquisition, Tian Tan Biological, another player in the blood products sector, will face increased competition as both companies operate in the same industry [6]. - There are expectations that China National Pharmaceutical may integrate Pailin Biological into Tian Tan Biological, enhancing operational efficiency and market share [8]. - If the integration occurs, the combined entity would control at least 123 plasma collection stations, with a total collection volume exceeding 4,000 tons, significantly outpacing competitors like Shanghai Raist and Hualan Biological [8][9].

Economic Overview - In 2024, Shandong's GDP reached 98,565.8 billion yuan, growing by 5.7% year-on-year, with the primary, secondary, and tertiary industries contributing 6.7%, 40.2%, and 53.1% respectively [2] - The province's listed companies are crucial for economic development, focusing on green, low-carbon, and high-quality growth while enhancing technological innovation [2] Performance of Listed Companies - Shandong's listed companies achieved a total revenue of 2.95 trillion yuan in 2024, a year-on-year increase of 4.61%, while net profit was 175.9 billion yuan, down 3.20% [4] - 78.96% of the companies reported profits, which is 5.27 percentage points higher than the national average, indicating better performance despite challenges in traditional industries [4][5] Contribution to Economic Growth - Listed companies in Shandong contributed 29.92% of the province's GDP, with an added value of 705.18 billion yuan, reflecting their significant role in regional economic growth [5] - The labor productivity of listed companies was 483,600 yuan per person, 2.78 times the national average, showcasing their efficiency [5] Innovation and Growth of SMEs - In 2024, 67 companies on the Growth Enterprise Market reported revenues of 177.98 billion yuan, up 15.13%, and net profits of 11.74 billion yuan, up 49.42%, indicating strong growth in innovative SMEs [6] - The total R&D expenditure for these companies was 6.44 billion yuan, a 8.11% increase, highlighting their commitment to innovation [6] Market Capitalization and Value Management - By the end of 2024, the market capitalization of Shandong's listed companies reached 3.63 trillion yuan, a 4.18% increase, ranking seventh nationally [8] - 125 companies conducted share buybacks, totaling 9.568 billion yuan, reflecting a strong commitment to value management [8] Characteristics of Listed Companies - Private listed companies in Shandong accounted for 62.14% of the total, achieving revenues of 838.06 billion yuan, up 4.64%, and net profits of 431.87 billion yuan, up 16.49% [9][10] - Companies with overseas business generated 842.85 billion yuan in foreign income, a year-on-year increase of 8.89%, indicating the importance of international markets [12] Mergers and Acquisitions - In 2024, 13 listed companies in Shandong participated in mergers and acquisitions, with a total transaction value of 38.75 billion yuan, a 3.58-fold increase [14][15] - The trend of state-owned enterprises merging with peers is becoming more common, enhancing market competitiveness [15] Sustainable Development and ESG - Shandong's listed companies showed a 44.34% ESG report disclosure rate, slightly above the national average, indicating a growing recognition of sustainability [16][17] - The average ESG score for Shandong's companies was 5.79, higher than the national average, with two companies scoring above 9.00 [17] Innovation and Digital Transformation - R&D expenses for Shandong's listed companies reached 84.51 billion yuan, a 3.94% increase, with a focus on enhancing innovation capabilities [18] - The digital economy's core companies reported revenues of 330.38 billion yuan, up 27.57%, demonstrating significant growth in this sector [20] Traditional Industry Transformation - Traditional industries in Shandong are undergoing digital and intelligent transformations, with companies like Shandong High-Speed adopting advanced technologies to enhance operational efficiency [23] - The integration of digital and green technologies is seen as essential for fostering new productive forces in traditional sectors [24]

证券代码：002252 证券简称：上海莱士 公告编号：2025-044 上海莱士血液制品股份有限公司 关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 上海莱士血液制品股份有限公司（"公司"）于 2025 年 1 月 13 日召开了第六 届董事会第七次（临时）会议，审议通过了《关于回购公司股份方案的议案》， 同意公司使用自有或自筹资金以集中竞价交易方式从二级市场回购公司股份，用 于实施员工持股计划或股权激励，拟回购股份的资金总额为不低于人民币 2.5 亿 元（含）且不超过人民币 5 亿元（含），拟回购股份价格不超过人民币 9.55 元/ 股（含），具体回购股份数量以回购股份方案实施完毕或回购实施期限届满时实 际回购情况为准。回购期限自股东大会审议通过本次回购股份方案之日起 12 个 月内，如果触及回购股份方案提及的相关条件时，回购期限提前届满。公司于 2025 年 2 月 14 日召开 2025 年第一次临时股东大会审议通过了上述股份回购方 案。具体内容详见公司分别于 2025 年 1 月 14 日、2025 年 2 月 15 日在《 ...

Group 1 - The Shanghai Composite Index opened lower but rose throughout the day, with the CSI 300 Pharmaceutical and Biotechnology Index reported at 7971.61 points [1] - The CSI 300 Pharmaceutical and Biotechnology Index has increased by 5.53% in the past month, 7.39% in the past three months, and 7.09% year-to-date [1] - The CSI 300 Index categorizes its 300 sample stocks into 11 primary industries, 35 secondary industries, over 90 tertiary industries, and more than 200 quaternary industries [1] Group 2 - The top ten holdings of the CSI 300 Pharmaceutical and Biotechnology Index are: Heng Rui Medicine (25.29%), WuXi AppTec (16.43%), Pian Zai Huang (6.37%), Yunnan Baiyao (5.21%), Kelun Pharmaceutical (5.11%), East China Pharmaceutical (4.06%), Xinhecheng (3.51%), Changchun High-tech (3.48%), Fosun Pharma (3.34%), and Shanghai Raas (3.27%) [1] - The market segments of the CSI 300 Pharmaceutical and Biotechnology Index show that the Shanghai Stock Exchange accounts for 63.65% and the Shenzhen Stock Exchange accounts for 36.35% [2] - The industry composition of the CSI 300 Pharmaceutical and Biotechnology Index includes: chemical drugs (43.80%), pharmaceutical and biotechnology services (21.66%), traditional Chinese medicine (18.52%), and biological drugs (16.02%) [2] Group 3 - The index samples are adjusted every six months, with adjustments implemented on the next trading day following the second Friday of June and December each year [2] - Weight factors are adjusted along with the periodic sample adjustments, which are generally fixed until the next scheduled adjustment [2] - Temporary adjustments occur when the CSI 300 Index samples are modified, and changes in industry classification due to special events will also lead to corresponding adjustments in the CSI 300 industry index samples [2]

Group 1 - The Shanghai Composite Index opened high and fluctuated, with the CSI 300 Pharmaceutical and Biotechnology Index reported at 7798.06 points [1] - The CSI 300 Pharmaceutical and Biotechnology Index has increased by 4.26% in the past month, 2.71% in the past three months, and 4.75% year-to-date [1] - The CSI 300 Index samples are categorized into 11 primary industries, 35 secondary industries, over 90 tertiary industries, and more than 200 quaternary industries [1] Group 2 - The top ten weights in the CSI 300 Pharmaceutical and Biotechnology Index are: Heng Rui Medicine (25.23%), WuXi AppTec (16.45%), Pian Zai Huang (6.51%), Yunnan Baiyao (5.3%), Kelun Pharmaceutical (5.04%), East China Pharmaceutical (3.91%), New Horizon (3.59%), Changchun High-tech (3.57%), Shanghai Raist (3.34%), and Fosun Pharmaceutical (3.18%) [1] - The market share of the CSI 300 Pharmaceutical and Biotechnology Index is 63.57% from the Shanghai Stock Exchange and 36.43% from the Shenzhen Stock Exchange [2] - The industry composition of the index includes: Chemical drugs (43.24%), Pharmaceutical and Biotechnology services (21.56%), Traditional Chinese medicine (18.83%), and Biological drugs (16.37%) [2] Group 3 - The index samples are adjusted every six months, with adjustments implemented on the next trading day after the second Friday of June and December each year [2] - Weight factors are generally fixed until the next scheduled adjustment, with temporary adjustments made when the CSI 300 Index samples are modified [2] - Special events affecting sample companies may lead to changes in industry classification and subsequent adjustments to the CSI 300 industry index samples [2]

Group 1 - This week, 10 listed companies announced share buybacks and capital increase through special loans, including Weichai Power, which received a commitment letter for a buyback loan not exceeding 900 million yuan [1][2] - Weichai Power plans to repurchase shares amounting to 500 million to 1 billion yuan to cancel and reduce its registered capital [1][2] Group 2 - Jianyou Co. announced a buyback with loan support not exceeding 36 million yuan on May 22 [2] - Gongniu Group received a commitment letter for a buyback loan not exceeding 360 million yuan on May 22 [2] - Fenda Technology obtained a commitment letter for a buyback loan not exceeding 90 million yuan on May 21 [2] - Xingshuai Er received a commitment letter for a buyback loan not exceeding 34.55 million yuan on May 20 [2] - Hexing Packaging plans to repurchase shares between 50 million to 100 million yuan with a loan not exceeding 90 million yuan [2] - Anhui Construction's controlling shareholder received loan support not exceeding 180 million yuan for capital increase on May 23 [2] - Hubei Yihua's controlling shareholder obtained a commitment letter for a capital increase loan not exceeding 360 million yuan on May 22 [2] - Tunnel Co.'s controlling shareholder received loan support not exceeding 450 million yuan for capital increase on May 22 [2] - Shanghai Laishi's controlling shareholder plans to increase shares between 250 million to 500 million yuan with a loan not exceeding 450 million yuan [2]

截至2025年5月23日收盘，上海莱士（002252）报收于6.8元，较上周的6.76元上涨0.59%。本周，上海 莱士5月22日盘中最高价报6.93元。5月19日盘中最低价报6.73元。上海莱士当前最新总市值451.38亿 元，在生物制品板块市值排名3/50，在两市A股市值排名290/5148。 公司公告汇总 关于控股股东增持股份计划的公告。证券代码：002252 证券简称：上海莱士 公告编号：2025-043。控 股股东海盈康（青岛）医疗科技有限公司基于对公司未来发展的信心和长期投资价值的认同，计划自本 公告披露之日起6个月内，通过深圳证券交易所交易系统以集中竞价交易方式增持公司股份，增持总金 额不低于人民币25,000万元，且不超过人民币50,000万元，不设置价格区间。本次增持计划资金来源为 自有资金及股份增持专项贷款，其中专项贷款资金占比不超过90%，中国银行股份有限公司青岛市分行 为海盈康提供不超过4.5亿元的股票增持专项贷款支持。海盈康承诺在增持期间及法定期限内不减持公 司股份，不进行内幕交易、短线交易等行为。本次增持计划不触及要约收购，不会导致公司股权分布不 符合上市条件，不会导致公司控制权发 ...